

## REMARKS

Claims 43-45, 47-48, 50-51, 57-58, 60-61, and 63-64 are canceled without prejudice or disclaimer. Claim 46 is amended to incorporate the limitations of canceled allowable claims 47-48; claim 49 is amended to incorporate the limitations of canceled allowable claims 50-51; claims 52-56 are amended to correct dependency; claim 59 is amended to incorporate the limitations of canceled allowable claims 60-61; and claim 62 is amended to incorporate the limitations of canceled allowable claims 63-64.

These amendments are believed to place the application in condition for allowance. The remaining rejections under the first paragraph of § 112 and under §103 are rendered moot by claim cancellation and/or amendment. No new matter is added by these amendments, and the examiner is respectfully requested to enter them.

### I. Rejection under §112, first paragraph.

Claims 43, 46, 49, 57-59, and 62 were rejected for lack of enablement. Claims 43 and 57-58 are canceled, and claims 46, 49, 59, and 62 are amended consistently with the Examiner's finding of enablement. Accordingly, it is believed that this rejection may now be withdrawn.

### II. Rejection under §103(a).

Claims 43-45, 49 and 52-58 were rejected as obvious over Anderson et al. Claims 43-45 and 57-58 are canceled, and claims 49 and 52-56 are amended consistently with the Examiner's finding of allowability. Accordingly, it is believed that this rejection may now be withdrawn.

### III. Claim Objections

Claims 47-48, 50-51, 60-61, and 63-64 were found to be allowable over the prior art. The limitations of these claims have been added to the claim from which they depend. Accordingly, it

USSN 10/055,842

Amendment dated 14 November 2003

Reply to Office Action of 4 September 2003


is believed that these amendments place the remaining claims in condition for allowance, and that

this objection is thus rendered moot.

#### IV. Fees

A response to the Office Action that was mailed by the United States Patent and Trademark Office on 4 September 2003 is due on 4 December 2003, and as such this response is being timely filed. No fee is deemed necessary in connection with filing this paper. However, if any fee is necessary, please charge such fee to Deposit Account Number 18-0650.

Respectfully submitted

  
Valeta Gregg, Ph.D., Reg. No. 35,127  
Regeneron Pharmaceuticals, Inc.  
777 Old Saw Mill River Road  
Tarrytown, New York 10591  
(914) 345-7400